SELECT-D: Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism: a prospective, randomised, open label, multicentre pilot study
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Rivaroxaban (Primary) ; Dalteparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-D
- 13 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results obtaining the outcomes from CARAVAGGIO, HOKUSAI-VTE, ADAM VTE and SELECT-D and analysing Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism, presented at the 57th Annual Meeting of the American Society of Clinical Oncology